KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) FCF Margin (2023 - 2025)

Biocryst Pharmaceuticals' FCF Margin history spans 9 years, with the latest figure at 41386.72% for Q4 2025.

  • For Q4 2025, FCF Margin rose 4139120.0% year-over-year to 41386.72%; the TTM value through Dec 2025 reached 73.94%, up 8573.0%, while the annual FY2025 figure was 39.64%, 5143.0% up from the prior year.
  • FCF Margin reached 41386.72% in Q4 2025 per BCRX's latest filing, up from 25.74% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 41386.72% in Q4 2025 to a low of 58.13% in Q1 2024.
  • Average FCF Margin over 3 years is 4595.44%, with a median of 1.39% recorded in 2024.
  • Peak YoY movement for FCF Margin: tumbled -223bps in 2024, then surged 4139120bps in 2025.
  • A 3-year view of FCF Margin shows it stood at 2.25% in 2023, then tumbled by -99bps to 4.48% in 2024, then surged by 924652bps to 41386.72% in 2025.
  • Per Business Quant, the three most recent readings for BCRX's FCF Margin are 41386.72% (Q4 2025), 25.74% (Q3 2025), and 24.72% (Q2 2025).